Asia Pacific Lyophilization Services for Biopharmaceuticals Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Service Type (Lyophilization Cycle Development, Clinical Manufacturing, Commercial Manufacturing, and Freeze-Drying Analytical

Asia Pacific Lyophilization Services for Biopharmaceuticals Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Service Type (Lyophilization Cycle Development, Clinical Manufacturing, Commercial Manufacturing, and Freeze-Drying Analytical Services) and End User (Pharmaceutical & Biotechnology Companies, Research Institutes, and Others)

The Asia Pacific lyophilization services for biopharmaceuticals market is expected to grow from US$ 334.18 million in 2023 to US$ 551.97 million by 2028. It is estimated to register a CAGR of 10.6% from 2023 to 2028.

Launch of Advanced Lyophilization Technologies Fuels Asia Pacific Lyophilization Services for Biopharmaceuticals Market

Biopharmaceutical companies in the lyophilization services market are launching advanced lyophilization technologies to expand their business and maintain a competitive environment in the market. In August 2022, Leadgene Biomedical, Inc., an ISO-certificated contract development and manufacturing organization (CDMO) providing integrated services for in-vitro diagnostics (IVD) products from the development to manufacturing process, launched LEADSPHERE Lyophilization Technology. The technology aids in dispensing, storing, and transporting reagents for use in biomolecule analysis tools. It also allows assay reagents to be stable in the nonliquid form at room temperature and enables the assembling of the complete kit in a large-scale production manner through a 'pick and place' automation system. A successful example that uses LEADSPHERE Lyophilization Technology is the LEADSPHERE Proteinase K, an endopeptidase used for nucleic acids sample preparation by inactivating ribonuclease and digesting proteins. LEADSPHERE Proteinase K has been used in applications to detect viruses, such as SARS-CoV-2.

In May 2022, PCI Pharma Services (PCI), a leading global CDMO, announced a major expansion of capacity and capabilities in sterile lyophilization technology and aseptic liquid fill-finish—an important manufacturing process commonly used with injectable and biologic therapies—with an investment of US$ 100 million in the construction and enhancement of world-class facilities at its Bedford, New Hampshire campus. The facility will contain state-of-the-art technology, including an aseptic fill-finish line with a completely isolated containment system. Also, it will hold twin lyophilizers with autoloading and unloading systems, with the capacity to complete 400 vials/minute on a sterile fill-finish line.

The launch of such advanced lyophilization technologies is likely to offer opportunities for players operating in the lyophilization services for biopharmaceuticals market to attain a significant position in the coming years.

Asia Pacific Lyophilization Services for Biopharmaceuticals Market Overview

Asia Pacific is the fastest-growing market for lyophilization services for biopharmaceuticals globally. The market in Asia Pacific is segmented into China, India, Japan, Australia, South Korea, and the Rest of Asia Pacific. China, Japan, and India widely contribute to market growth. The increasing production of biopharmaceutical products is likely to demand lyophilization services in these countries. Also, the rising investments in domestic companies are expected to influence the market growth during the forecast period.

On the other hand, countries such as South Korea and Australia serve vital growth opportunities due to rising clinical trials. Growing investment in research and development is likely to contribute to market growth.

Asia Pacific Lyophilization Services for Biopharmaceuticals Market Revenue and Forecast to 2028 (US$ Million)

Asia Pacific Lyophilization Services for Biopharmaceuticals Market Segmentation

The Asia Pacific lyophilization services for biopharmaceuticals market is segmented into service type, end user, and country.

Based on service type, the Asia Pacific lyophilization services for biopharmaceuticals market is segmented into lyophilization cycle development, clinical manufacturing, commercial manufacturing, and freeze-drying analytical services. The commercial manufacturing segment held the largest share of the Asia Pacific lyophilization services for biopharmaceuticals market in 2023.

By end user, the Asia Pacific lyophilization services for biopharmaceuticals market is segmented into pharmaceutical & biotechnology companies, research institutes, and others. The pharmaceutical & biotechnology companies segment held the largest share of the Asia Pacific lyophilization services for biopharmaceuticals market in 2023.

Based on country, the Asia Pacific lyophilization services for biopharmaceuticals market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. China dominated the Asia Pacific lyophilization services for biopharmaceuticals market in 2023.

Curia Global Inc, Emergent BioSolutions Inc, Jubilant HollisterStier LLC., and PCI Pharma Services are the leading companies operating in the Asia Pacific lyophilization services for biopharmaceuticals market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific lyophilization services for biopharmaceuticals market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in Asia Pacific lyophilization services for biopharmaceuticals market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.